Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.044
Neutral
RSI(14)
51.854
Neutral
STOCH(KDJ)(9,3,3)
9.868
Oversold
ATR(14)
0.393
Low Volatility
CCI(14)
-109.033
Sell
Williams %R
79.366
Sell
TRIX(12,20)
1.281
Sell
StochRSI(14)
0.000
Oversold
LifeMD Inc
LFMD3.665USD
-0.275-6.98%
Market hours （ET）Quotes delayed by 15 min
21.24MMarket Cap
14.71P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of LifeMD Inc
Currency: USD Updated: 2026-03-27Key Insights
LifeMD Inc's fundamentals are relatively healthy, with low ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 81 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.75.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LifeMD Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
LifeMD Inc Highlights
StrengthsRisks
LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 27.21% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 14.93, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.69M shares, decreasing 27.06% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 3.48K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.53.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
9.750
Target Price
+147.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of LifeMD Inc is 6.75, ranking 116 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 46.87M, representing a year-over-year decrease of 27.06%, while its net profit experienced a year-over-year decrease of 2273.35%.
Score
Financials
7.58
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.70
Operational Efficiency
6.62
Growth Potential
5.76
Shareholder Returns
7.11
LifeMD Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of LifeMD Inc is 7.91, ranking 52 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 14.93, which is 19.35% below the recent high of 17.81 and 539.55% above the recent low of -65.61.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 81/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of LifeMD Inc is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 8.50, with a high of 15.00 and a low of 6.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
9.750
Target Price
+147.46%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
92
Total
4
Median
7
Average
Company name
Ratings
Analysts
LifeMD Inc
LFMD
8
Boston Scientific Corp
BSX
36
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of LifeMD Inc is 7.39, ranking 20 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 4.77 and the support level at 2.63, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.884
Sell
MA10
4.036
Sell
MA20
3.715
Sell
MA50
3.368
Buy
MA100
3.683
Sell
MA200
6.099
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of LifeMD Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 42.98%, representing a quarter-over-quarter decrease of 19.82%. The largest institutional shareholder is The Vanguard, holding a total of 2.02M shares, representing 4.21% of shares outstanding, with 1.85% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Schreiber (Justin)
BlackRock Institutional Trust Company, N.A.
Galluppi (Stefan)
State Street Investment Management (US)
Geode Capital Management, L.L.C.
Citadel Advisors LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of LifeMD Inc is 3.63, ranking 120 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.75. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. LifeMD Inc’s latest ESG disclosure lags behind the Healthcare Equipment & Supplies industry average, suggesting potential exposures in governance structure, environmental management, or social responsibility that may amplify risk and warrant ongoing monitoring.
Score
Beta vs S&P 500 index
1.62
VaR
+7.67%
240-Day Maximum Drawdown
+82.47%
240-Day Volatility
+98.04%
Return
Best Daily Return
60 days
+25.32%
120 days
+25.32%
5 years
+41.31%
Worst Daily Return
60 days
-9.77%
120 days
-13.53%
5 years
-44.85%
Sharpe Ratio
60 days
+0.78
120 days
-1.17
5 years
+0.13
Risk Assessment
Maximum Drawdown
240 days
+82.47%
3 years
+82.47%
5 years
+91.76%
Return-to-Drawdown Ratio
240 days
-0.32
3 years
+0.42
5 years
-0.16
Skewness
240 days
+0.23
3 years
+0.00
5 years
+0.12
Volatility
Realised Volatility
240 days
+98.04%
5 years
+92.88%
Standardised True Range
240 days
+12.54%
5 years
+10.93%
Downside Risk-Adjusted Return
120 days
-211.85%
240 days
-211.85%
Maximum Daily Upside Volatility
60 days
+91.80%
Maximum Daily Downside Volatility
60 days
+59.44%
Liquidity
Average Turnover Rate
60 days
+4.52%
120 days
+4.29%
5 years
--
Turnover Deviation
20 days
+153.41%
60 days
+77.90%
120 days
+68.86%
Peer Comparison
Healthcare Equipment & Supplies
LifeMD Inc
LFMD
6.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
